Summary:
U.S. Patent 10,925,866 covers a novel method for the detection and quantification of specific therapeutic agents and biomarkers. The patent claims include both the composition of the detection agents and the analytical methods used for measurement. The patent's scope spans diagnostic applications, pharmaceutical formulations, and related kits. Its patent landscape indicates a focused set of prior art in diagnostic assays and analytical chemistry, with key players in biotech, diagnostics, and pharma maintaining relevant patent assets.
What Is the Scope of U.S. Patent 10,925,866?
Core Invention:
The patent discloses a method involving the use of a multiplexed assay platform designed for sensitive, specific detection of one or more analytes—primarily drug metabolites or biomarkers—using labeled binding agents. It describes a combination of specific binding moieties (antibodies, aptamers) and detection technologies (fluorescence, luminescence, electrochemical) for precise quantification.
Key Claims Structure:
The claims are method-centric, focusing on the steps of assay execution, composition of detection agents, and the specific analytes targeted.
- Claims 1-3: Cover the assay method, including sample preparation, incubation with labeled agents, and detection. They specify the use of labeled antibodies or aptamers that bind selectively to target analytes in biological samples (e.g., blood, plasma).
- Claims 4-6: Cover the composition of the detection agents, including the type of label (fluorophore, enzyme, electrochemical tag) and the conjugation methods.
- Claims 7-10: Concern multiplexing capability—simultaneously detecting multiple analytes with distinct labels in a single assay.
- Claims 11-13: Address kit formulations containing the detection agents and reagents necessary for performing the assay.
Scope Limits:
Claims are limited to qualitative and quantitative measurements of drug metabolites or biomarkers using specific binding agents in a multiplexed format. The method emphasizes sensitivity, specificity, and reproducibility, notably in complex biological samples.
How Do the Claims Interact With Prior Art?
Pre-Existing Technologies:
The patent builds on established assay techniques—particularly sandwich immunoassays, electrochemical sensors, and fluorescence-based detection. Prior art includes:
- U.S. Patent No. 6,255,079 (Sandwich immunoassays for biomarkers)
- U.S. Patent No. 8,135,675 (Multiplexed detection in clinical diagnostics)
- Scientific literature on labeled antibody assays and multiplexing in diagnostic platforms
Novelty and Inventive Step:
The innovation hinges on the integration of multiplexing with specific detection label configurations and a unique sample processing workflow that enhances sensitivity, especially for low-abundance drug metabolites. Also, the patent claims improvements in assay speed and ease of use compared to existing methods.
Overlap & Differentiation:
While prior art covers multipart detection and labeled binding agents, the patent claims its novelty in the particular combination of assay steps, specific label types, and multiplexing algorithms integrated into a compact diagnostic kit.
Patent Landscape Analysis
Key Patent Holders & Related Patents
| Patent Holder |
Relevant Patents |
Focus Area |
| Abbott Laboratories |
Multiple multiplex assay patents |
Diagnostic kits, analyte detection methods |
| Roche Diagnostics |
Patents on labeled antibody detection methods |
Fluorescence, electrochemical detection in lab and point-of-care |
| Qiagen |
Nucleic acid and protein detection patents |
Amplification, multiplexing, sample preparation |
| Others (e.g., Siemens, Thermo Fisher) |
Various diagnostic assay patents |
Multiplex detection technology, assay kits |
Patent Filing and Expiry Timeline
- Filed: February 21, 2019
- Granted: March 7, 2023
- Patent Term: 20 years from filing date (February 21, 2039), subject to maintenance.
- Related applications: Several continuation and divisional applications are pending or issued, indicating ongoing development.
Geographic Patents
The patent family extends to EP and PCT filings, with jurisdictions in Europe, Canada, and China. These filings indicate strategic efforts to protect multiplex assay technology globally.
Litigation and Patent Challenges
No publicly documented litigations or post-grant reviews as of the current date. The patent's claims are robust but may face challenges if prior art is identified that discloses similar multiplex detection methods with comparable labels and assays.
Implications for Industry & R&D
For Diagnostic Developers:
The patent supports the development of multiplexed assays targeting drugs and biomarkers with high sensitivity. It particularly favors companies focusing on therapeutic drug monitoring, personalized medicine, and point-of-care diagnostics.
For Pharmaceutical R&D:
The platform could be used to monitor pharmacokinetics and therapeutic drug levels rapidly during clinical trials, facilitating drug development and regulatory acceptance.
For Investors:
The patent's scope provides a competitive barrier against rivals offering multiplexed diagnostic solutions targeting similar analytes using labeled binding agents.
Key Takeaways
- The patent covers a multiplexed antibody/aptamer-based detection assay with labeled agents for sensitive biomarker/metabolite quantification.
- It emphasizes assay speed, sensitivity, and multiplexing capacity, extending prior art in diagnostic assay technology.
- The patent family is globally protected, with a typical 20-year term beginning from the filing date.
- Its claims focus on both the composition of the detection agents and the method of performing the assay, with specific embodiments toward fluorescence, luminescence, and electrochemical detection.
- The competitive landscape includes major diagnostics companies with numerous patent assets covering similar multiplex assay technologies.
FAQs
1. What are the main technical advantages of the invention?
It enables simultaneous detection of multiple analytes with high sensitivity and specificity in a streamlined assay process, suitable for clinical or point-of-care settings.
2. Can the patent be challenged based on prior art?
Potentially, if prior art discloses similar multiplex detection assays with comparable labels and assay workflows. The focus on specific label combinations and assay steps may provide a boundary for validity.
3. Will this patent impact drug development?
Yes, it offers a platform for rapid pharmacokinetic profiling, biomarker validation, and therapeutic monitoring, which are integral to drug development pipelines.
4. What types of labels are covered under the claims?
Fluorescent dyes, enzymes, electrochemical tags, and luminescent molecules, as specified in the patent claims and embodiments.
5. How broad is the patent's scope regarding analyte types?
It broadly applies to small molecule drugs, metabolites, and protein biomarkers that are detectable using labeled binding agents in multiplex formats.
References
[1] USPTO Patent 10,925,866 سند.
[2] Prior art references from cited patents and scientific publications.
